Navigation Links
Dendreon Announces Election of Dr. David C. Stump to Board of Directors
Date:6/2/2010

SEATTLE, June 2 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) today announced that David C. Stump, M.D., has been elected to the Company's Board of Directors.  Dr. Stump is currently executive vice president of research and development for Human Genome Sciences, Inc. (Nasdaq: HGSI), where he has been a member of its management committee since 1999.

"We welcome Dave to Dendreon's Board of Directors.  With more than 20 years of experience in global drug development and clinical research, Dave is an ideal addition to our board, particularly as Dendreon initiates its ex-U.S. strategy and expands its clinical development program to develop new and innovative treatment options for cancer patients," said Richard B. Brewer, chairman of the Dendreon Board of Directors.  

Prior to joining Human Genome Sciences, Inc., Dr. Stump held positions of increasing responsibility over a decade at Genentech, Inc., including vice president of clinical research.  He was named a Genentech Fellow in 1996 for leadership of its cardiovascular drug development activities.  In his later roles he was also responsible for pulmonary, oncology, and neuroendocrine clinical development programs.  He served as a member of the research review, clinical review, and product development committees which were responsible for oversight of all internal and external research and development opportunities.  Prior to Genentech, Dr. Stump served as associate professor of medicine and biochemistry at the University of Vermon
'/>"/>

SOURCE Dendreon Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Dendreon Announces Webcast Presentation at UBS Life Sciences Conference
3. Dendreon Secures $130 Million Committed Equity Financing Facility
4. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
5. Dendreon Reports Third Quarter 2007 Financial Results
6. Dendreon Promotes Dr. Mark Frohlich to Senior Vice President of Clinical Affairs and Chief Medical Officer
7. Dendreon Announces Webcast Presentation at BIO CEO & Investor Conference
8. Dendreon Publishes Manuscript on CD54 as a Surrogate Marker of Antigen Presenting Cell Activation
9. -Dendreon to Hold Conference Call on Thursday, March 13, 2008 at 11:00 AM ET-
10. FDA Agrees to Amend Dendreons Special Protocol Assessment for Phase 3 IMPACT Study of PROVENGE
11. Dendreon Reports Fourth Quarter and 2007 Year End Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2014)... 14, 2014 Throughout this past ... the clinical trials space, representing 38 countries globally, ... entitled “Optimizing Patient Participation in Clinical Trials. Attract. ... with internationally renowned R&D expert, Ken Getz, of ... Reinventing Drug Development through Patient Centricity. , Throughout ...
(Date:7/13/2014)... 2014 Deep Research Report on Global and ... study on the current state of the Nano Silver ... a basic overview of the industry, including definitions, applications ... domestic market analysis are provided with a focus on ... A comparison between the international and Chinese situation is ...
(Date:7/11/2014)... , July 11, 2014 Research ... "International Transfection Technology Market - Global Industry Analysis, Size, ... to their offering. http://photos.prnewswire.com/prnh/20130307/600769 ... introduce nucleic acids (either DNA or RNA) into cells. ... mutation of cancer cells and protein metabolism by affecting ...
(Date:7/11/2014)... , July 11, 2014  Researchers have ... three-dimensional images. The new technology, called Virtual Finger, ... small structures like neurons and synapses using the ... unique technology makes 3D imaging studies orders of ... at an unprecedented level across many areas of ...
Breaking Biology Technology:Optimizing Patient Participation in Clinical Trials: Attract. Engage. Retain. – eCongress eBox Archives Now Available 2Optimizing Patient Participation in Clinical Trials: Attract. Engage. Retain. – eCongress eBox Archives Now Available 3Optimizing Patient Participation in Clinical Trials: Attract. Engage. Retain. – eCongress eBox Archives Now Available 4Optimizing Patient Participation in Clinical Trials: Attract. Engage. Retain. – eCongress eBox Archives Now Available 52014 Nano Silver Industry in Global and China Regions Development Proposals Analysis Available at DeepResearchReports.com 22014 Nano Silver Industry in Global and China Regions Development Proposals Analysis Available at DeepResearchReports.com 3International Transfection Technology Market - Industry Analysis, Size, Share, Growth, Trends and Forecast to 2019 2Virtual Finger Enables Scientists To Navigate And Analyze 3D Images Of Complex Biological Structures 2Virtual Finger Enables Scientists To Navigate And Analyze 3D Images Of Complex Biological Structures 3
... , for routine high fidelity amplification of up to 3.5 kb , ... 100 units , Cat. No. 1 664 955 ... , , Description , , , ... archaebacterium Pyrococcus woesei. The enzyme has a molecular weight of , ...
... , for routine amplification of up to 3 kb genomic DNA ... , , , , , ... contains 10 vials of 2x concentrated PCR reaction , mix (Taq ... dNTPs) plus water PCR grade (for dilution), sufficient for 100 , ...
... for amplification of up to 5 kb targets from genomic DNA ... , , , , , ... concentrated High Fidelity PCR Master contains all necessary , reagents ... a unique enzyme blend of Taq DNA Polymerase and Pwo DNA Polymerase[a thermostable , ...
Cached Biology Technology:Pwo DNA Polymerase 2Pwo DNA Polymerase 3PCR Master 2PCR Master 3High Fidelity PCR Master 2
(Date:7/11/2014)... from Ume University, Sweden, have explored two different ... reaction sequence leading to the formation of oxygen ... published in the scientific journal Nature Communications ... present day synthetic catalysts for water oxidation, which ... for the direct storage of solar energy in ...
(Date:7/11/2014)... that transplantation of mesenchymal stem cells can stimulate neurogenesis ... of Alzheimer,s disease (AD) and improve tissue and function ... are reported on the therapeutic effect of adipose-derived stem ... the effect on oxidative injury and neurogenesis in the ... team, School of Life Sciences, Tsinghua University, China transplanted ...
(Date:7/11/2014)... Evidence exists that cannabinoid receptor type 1 ... Ca2+ influx, and reduce neurotransmitter release. However, ... 1 can increase extracellular Ca2+ influx and ... his team, Tongji Hospital Affiliated to Tongji ... Technology, China used whole cell voltage-clamp and ...
Breaking Biology News(10 mins):Molecular snapshots of oxygen formation in photosynthesis 2
... electronic skin, or e-skin, and electronic eye implants or ... Researchers with Berkeley Lab and the University of California ... of carbon nanotubes and silver nanoparticles similar to the ... e-whiskers respond to pressure as slight as a single ...
... of men,s bones - but only if they marry when they,re ... In a study published online in the peer-reviewed journal Osteoporosis ... were younger than 25 had lower bone strength than men who ... In addition, men in stable marriages or ...
... climate. Take, for example, the Mayans, who, throughout the ... their major ceremonial centers after a series of multi-year droughts, ... forests. Much later, in the late 20th century, frequent droughts ... migrate from the dry north to the wetter south where ...
Cached Biology News:E-whiskers 2Guys: Get married for the sake of your bones, but wait until you're 25 2Guys: Get married for the sake of your bones, but wait until you're 25 3Princeton model anticipates ecological impacts of human responses to climate 2Princeton model anticipates ecological impacts of human responses to climate 3